INTRODUCTION: Autoimmune hepatitis and cholestatic liver diseases have more favorable outcomes after liver transplantation as compared to viral hepatitis and alcoholic liver diseases. However, there are only few reports comparing outcomes of both living donor liver transplants (LDLT) and deceased donor liver transplants (DDLT) for these conditions. AIM: We aim to study the survival outcomes of patients undergoing LT for autoimmune and cholestatic diseases and to identify possible risk factors influencing survival. Survival outcomes for LDLT vs. DDLT are also to be compared for these diseases. PATIENTS AND METHODS: A retrospective analysis of the UNOS database for patients transplanted between February 2002 until October 2006 for AIH, PSC, and PBC was performed. Survival outcomes for LDLT and DDLT patients were analyzed and factors influencing survival were identified. RESULTS: Among all recipients the estimated patient survival at 1, 3, and 5 years for LDLT was 95.5%, 93.6%,and 92.5% and for DDLT was 90.9%, 86.5%, and 84.9%, respectively (p = 0.002). The estimated graft survival at 1, 3, and 5 years for LDLT was 87.9%, 85.4%, and 84.3% and for DDLT 85.9%, 80.3%, and 78.6%, respectively (p = 0.123). On multivariate proportional hazard regression analysis after adjusting for age and MELD score, the effect of donor type was not found to be significant. CONCLUSION: The overall survival outcomes of LDLT were similar to DDLT in our patients with autoimmune and cholestatic liver diseases. It appears from our study that after adjusting for age and MELD score donor type does not significantly affect the outcome.
INTRODUCTION:Autoimmune hepatitis and cholestatic liver diseases have more favorable outcomes after liver transplantation as compared to viral hepatitis and alcoholic liver diseases. However, there are only few reports comparing outcomes of both living donor liver transplants (LDLT) and deceased donor liver transplants (DDLT) for these conditions. AIM: We aim to study the survival outcomes of patients undergoing LT for autoimmune and cholestatic diseases and to identify possible risk factors influencing survival. Survival outcomes for LDLT vs. DDLT are also to be compared for these diseases. PATIENTS AND METHODS: A retrospective analysis of the UNOS database for patients transplanted between February 2002 until October 2006 for AIH, PSC, and PBC was performed. Survival outcomes for LDLT and DDLT patients were analyzed and factors influencing survival were identified. RESULTS: Among all recipients the estimated patient survival at 1, 3, and 5 years for LDLT was 95.5%, 93.6%,and 92.5% and for DDLT was 90.9%, 86.5%, and 84.9%, respectively (p = 0.002). The estimated graft survival at 1, 3, and 5 years for LDLT was 87.9%, 85.4%, and 84.3% and for DDLT 85.9%, 80.3%, and 78.6%, respectively (p = 0.123). On multivariate proportional hazard regression analysis after adjusting for age and MELD score, the effect of donor type was not found to be significant. CONCLUSION: The overall survival outcomes of LDLT were similar to DDLT in our patients with autoimmune and cholestatic liver diseases. It appears from our study that after adjusting for age and MELD score donor type does not significantly affect the outcome.
Authors: A González-Koch; A J Czaja; H A Carpenter; S K Roberts; M R Charlton; M K Porayko; C B Rosen; R H Wiesner Journal: Liver Transpl Date: 2001-04 Impact factor: 5.799
Authors: C E Garcia; R F L Garcia; B Gunson; E Christensen; J Neuberger; P McMaster; D F Mirza Journal: Exp Clin Transplant Date: 2004-06 Impact factor: 0.945
Authors: Phunchai Charatcharoenwitthaya; Sylvania Pimentel; Jayant A Talwalkar; Felicity T Enders; Keith D Lindor; Ruud A F Krom; Russell H Wiesner Journal: Liver Transpl Date: 2007-09 Impact factor: 5.799
Authors: J-C Duclos-Vallée; M Sebagh; K Rifai; C Johanet; E Ballot; C Guettier; V Karam; M Hurtova; C Feray; M Reynes; H Bismuth; D Samuel Journal: Gut Date: 2003-06 Impact factor: 23.059
Authors: Ian A Rowe; Kerry Webb; Bridget K Gunson; Naimish Mehta; Sayeed Haque; James Neuberger Journal: Transpl Int Date: 2008-01-21 Impact factor: 3.782
Authors: Mehmet Sayiner; Maria Stepanova; Leyla De Avila; Pegah Golabi; Andrei Racila; Zobair M Younossi Journal: Dig Dis Sci Date: 2019-08-27 Impact factor: 3.199
Authors: Kim M Olthoff; Abigail R Smith; Michael Abecassis; Talia Baker; Jean C Emond; Carl L Berg; Charlotte A Beil; James R Burton; Robert A Fisher; Chris E Freise; Brenda W Gillespie; David R Grant; Abhinav Humar; Igal Kam; Robert M Merion; Elizabeth A Pomfret; Benjamin Samstein; Abraham Shaked Journal: Ann Surg Date: 2015-09 Impact factor: 12.969
Authors: Fredric D Gordon; David S Goldberg; Nathan P Goodrich; Anna S F Lok; Elizabeth C Verna; Nazia Selzner; R Todd Stravitz; Robert M Merion Journal: Liver Transpl Date: 2016-08-02 Impact factor: 5.799
Authors: Maja Mijic; Ivona Saric; Bozena Delija; Milos Lalovac; Nikola Sobocan; Eva Radetic; Dora Martincevic; Tajana Filipec Kanizaj Journal: Can J Gastroenterol Hepatol Date: 2022-07-22
Authors: Vittorio Branchi; Tobias J Weismüller; Taotao Zhou; Jonas Henn; Alexander Semaan; Tim R Glowka; Maria Gonzalez-Carmona; Christian Strassburg; Jörg C Kalff; Steffen Manekeller; Hanno Matthaei Journal: Chirurg Date: 2021-02 Impact factor: 0.955